178 related articles for article (PubMed ID: 21316187)
1. Characteristics of and therapeutic options for contralateral axillary lymph node metastasis in breast cancer.
Morcos B; Jaradat I; El-Ghanem M
Eur J Surg Oncol; 2011 May; 37(5):418-21. PubMed ID: 21316187
[TBL] [Abstract][Full Text] [Related]
2. Locoregional recurrence in patients with triple-negative breast cancer: preliminary results of a single institution study.
Dragun AE; Pan J; Rai SN; Kruse B; Jain D
Am J Clin Oncol; 2011 Jun; 34(3):231-7. PubMed ID: 20805742
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options.
Gentilini O; Masullo M; Rotmensz N; Peccatori F; Mazzarol G; Smeets A; Simsek S; De Dosso S; Veronesi P; Intra M; Zurrida S; Viale G; Goldhirsch A; Veronesi U
Eur J Surg Oncol; 2005 Apr; 31(3):232-6. PubMed ID: 15780556
[TBL] [Abstract][Full Text] [Related]
4. [Pathologic diagnosis and histopathology record of breast cancer].
Cserni G; Francz M; Járay B; Kálmán E; Kovács I; Kulka J; Orosz Z; Udvarhelyi N; Vass L
Magy Onkol; 2010 Sep; 54(3):217-26. PubMed ID: 20870599
[No Abstract] [Full Text] [Related]
5. The presentation of contralateral axillary lymph node metastases from breast carcinoma: a clinical management dilemma.
Huston TL; Pressman PI; Moore A; Vahdat L; Hoda SA; Kato M; Weinstein D; Tousimis E
Breast J; 2007; 13(2):158-64. PubMed ID: 17319857
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI
J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459
[TBL] [Abstract][Full Text] [Related]
7. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
8. Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor.
Fehm T; Maul H; Gebauer S; Scharf A; Baier P; Sohn C; Jäger W; Gebauer G
Strahlenther Onkol; 2005 Sep; 181(9):580-6. PubMed ID: 16170485
[TBL] [Abstract][Full Text] [Related]
9. Correlation of DNA flow cytometry and hormone receptors with axillary lymph node status in patients with carcinoma of the breast.
Friedman NS; Freedman MD
Md Med J; 1994 Nov; 43(11):963-5. PubMed ID: 7808198
[TBL] [Abstract][Full Text] [Related]
10. Does the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: single-center experiences.
Oven Ustaalioglu BB; Bilici A; Kefeli U; Seker M; Yildirim E; Salepci T; Oncel M; Kement M; Gumus M
Oncology; 2010; 79(1-2):105-11. PubMed ID: 21088436
[TBL] [Abstract][Full Text] [Related]
11. [Loss of hormonal receptors expression from primary breast carcinoma to axillary lymph node metastases].
Cianga C; Cianga P; Cozma L; Diaconu C; Carasevici E
Rev Med Chir Soc Med Nat Iasi; 2003; 107(3):540-4. PubMed ID: 14756058
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up results of breast cancer patients with sentinel lymph node biopsy using periareolar injection.
Imasato M; Shimazu K; Tamaki Y; Taguchi T; Tanji Y; Kim SJ; Noguchi S
Am J Surg; 2010 Apr; 199(4):442-6. PubMed ID: 19596117
[TBL] [Abstract][Full Text] [Related]
13. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma.
Barth A; Craig PH; Silverstein MJ
Cancer; 1997 May; 79(10):1918-22. PubMed ID: 9149018
[TBL] [Abstract][Full Text] [Related]
14. Use of sentinel node biopsy expands.
Peres J
J Natl Cancer Inst; 2013 Oct; 105(19):1423-4. PubMed ID: 24052620
[No Abstract] [Full Text] [Related]
15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
16. A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer.
Woo SU; Bae JW; Kim CH; Lee JB; Koo BW
Ann Surg Oncol; 2008 Jan; 15(1):281-5. PubMed ID: 17763975
[TBL] [Abstract][Full Text] [Related]
17. Detection of hepatocyte growth factor/scatter factor receptor (c-Met) and MUC1 from the axillary fluid drainage in patients after breast cancer surgery.
Greenberg R; Barnea Y; Schneebaum S; Kashtan H; Kaplan O; Skornik Y
Isr Med Assoc J; 2003 Sep; 5(9):649-52. PubMed ID: 14509156
[TBL] [Abstract][Full Text] [Related]
18. Axillary tumour.
Martins A; Serrão V; Fiadeiro T; Lopes MP; Campos F; Pereira H; Rodrigues JC
Histopathology; 2008 Apr; 52(5):654-5. PubMed ID: 18312349
[No Abstract] [Full Text] [Related]
19. [Prognosis prediction of S-phase fraction and p53, c-erbB-2, estrogen receptor, progesterone receptor in axillary node-negative breast cancer].
Zhang S; Yuan Y; Wang X
Zhonghua Wai Ke Za Zhi; 1997 Aug; 35(8):475-7. PubMed ID: 10678068
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
